Eterna Therapeutics Long Term Debt

Eterna Therapeutics (ERNA) currently reports a long-term debt of $230K as of March 2026. That compares with $420K in the prior-year period — down 46.1% year over year. Use the charts on this page to explore Eterna Therapeutics's long-term debt history and peer comparisons.

Eterna Therapeutics's long-term debt decreased from $420K to $230K — a 46.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eterna Therapeutics reported $230K in long-term debt as of March 2026. That compares with $420K in the prior-year period — down 46.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $230K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eterna Therapeutics, and consider following ERNA for alerts when major investors trade the stock.

Eterna Therapeutics is classified in the Telecommunications sector. On long-term debt, it currently shows $230K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing ERNA with unrelated industries.